Analysis of Sympathetic Activity in Willis-Ekbom Disease
A legfontosabb adatok
- Ki végzi
- University Hospital, Montpellier
- Hol
- Montpellier (Franciaország)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 40 fő, tervezett
- Kezdés
- 2017. márc. 21.
- Várható befejezés
- 2027. okt. 5.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Sympathetic nervous activity measurement
- A regiszteradat frissítve
- 2025. október 2.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with restless legs syndrome (Willis-Ekbom disease), and healthy volunteers without it for comparison. It measures nerve activity that controls the heart and blood pressure.
- Életkor
- 18 to 74 years (18 or more and less than 75).
- Nem
- All sexes can join.
- A betegség stádiuma
- Patients: idiopathic (primary) restless legs syndrome for at least 3 years, symptoms at least 3 times a week, all 5 IRLSSG 2012 criteria, IRLS severity score ≥ 15, and periodic limb movements index > 10/hour.
- Korábbi kezelés
- Patients must not have taken dopaminergic agonists, pregabalin or gabapentin in the last 8 days. No one may take antidepressant, neuroleptic, sympathomimetic, sympatholytic, vasculotropic, dopamine agonist or opiate treatments.
- Biomarker vagy leletérték
- Patients: ferritin > 50 ng/ml.
A részvétel fő kizáró okai
- Pregnant or breastfeeding women, or people under legal protection or deprived of liberty.
- Cancer treated in the last 12 months.
- History of heart or blood vessel disease, high blood pressure, stroke or sleep apnea.
- Restless legs caused by kidney failure, hemochromatosis, nerve disorders or medicines.
- Healthy volunteers cannot join if they have Willis-Ekbom disease.
A regiszter feltételei, szó szerint
Mind a 5 feltétel megnézéseKevesebb
Ki vehet részt
- Non-specific inclusion criteria (CASE + CONTROL); 18 years-old or more, and less than 75 years-old; French-speaking; able to understand the study; signed written informed consent; affiliated to social security
- CASE-specific inclusion criteria; 5 " International RLS Study Group (IRLSSG) 2012 " positive criteria; RLS severity scale (IRLS) score ≥ 15; ferritin > 50 ng/ml; periodic limb movements index > 10/hour; idiopathic (or primary) Willis-Ekbom disease not treated with dopaminergic agonists or pregabalin or gabapentin in the last 8 days, at least 3 years of disease duration with symptoms recurring at least 3 times a week
Ki nem vehet részt
- Non-specific exclusion criteria (CASE + CONTROL); vulnerable subject : subject deprived of liberty or protected by law (trusteeship, legal guardianship), pregnant or breastfeeding woman; exclusion period after other research protocol; malignant neoplastic disease treated in the last 12 months; medical history of cardiovascular disease (ischemic heart disease, heart failure, stroke, hypertension, sleep apnea syndrome); antidepressant, neuroleptic, sympathomimetic, sympatholytic, vasculotropic, dopamine agonists, opiate treatments
- CASE-specific exclusion criteria; restless legs syndrome secondary to renal failure, hemochromatosis, neurologic disorders, iatrogenesis
- CONTROL-specific exclusion criteria - Willis-Ekbom Disease
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 74 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Franciaország.
- University Hospital of MontpellierMontpellier, FranciaországContact: Yves Dauvilliers, PhDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Willis-Ekbom disease (WED), also known as restless legs syndrome (RLS) is a common neurological sensorimotor disorder that typically impairs sleep and quality of life, likely consequent to a central dopaminergic dysfunction associated to brain iron deficiency. Periodic limb movements (PLMS) in sleep are present in 80% of patients with WED. PLMS are often associated with micro-arousals that contribute to sleep fragmentation and repeated increases of blood pressure and heart rate throughout the night, thus representing an increased risk for hypertension and cardiovascular diseases (CVD).
A teljes eredeti leírásKevesebb
Willis-Ekbom disease affects people with higher cardiovascular risk factors, such as advanced age, obesity, diabetes mellitus and hypercholesterolemia. However, previous observational, cross-sectional or longitudinal population-based studies on the association between RLS and CVD and hypertension showed controversial results.
While the pathophysiology of RLS is yet to be elucidated and is likely multifactorial, one theory involves a reduction in dopaminergic outflow to the preganglionic sympathetic neurons in the dorsal horn of the spinal cord. Dopamine inhibits preganglionic sympathetic neurons, therefore a reduction in dopamine may in turn increase sympathetic outflow.
Based on this notion, the investigators hypothesize an increase of sympathetic autonomic activity in Willis-Ekbom disease responsible for the recurrent increase in blood pressure and heart rate during sleep, which may play a role in increasing the risk of cardiovascular diseases.
The aim of this study is to analyze the autonomic nervous activity in patients with WED compared to healthy volunteers controls. The investigators will measure primarily the cardiac sympathetic activity by the 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy and secondarily the sympathetic nerve activity by the plasmatic pro inflammatory biomarkers and urinary catecholamine levels and the circadian variation of blood pressure and heart rate as assessed by the 24-hour ambulatory blood pressure monitoring.
A vizsgálat 2 csoportja
- Willis-Ekbom disease patients (CASE)A vizsgált kezelés
Kezelés: Sympathetic nervous activity measurement
- Healthy volunteers (CONTROL)A vizsgált kezelés
Kezelés: Sympathetic nervous activity measurement
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT02929732: ki vehet részt
- A regiszteradat frissítve
- 2025. október 2.